209 related articles for article (PubMed ID: 36645182)
1. Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation.
Chen JY; Agrawal S; Yi HP; Vallejo D; Agrawal A; Lee AP
Adv Healthc Mater; 2023 May; 12(12):e2203163. PubMed ID: 36645182
[TBL] [Abstract][Full Text] [Related]
2. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
3. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
Rhodes KR; Green JJ
Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
[TBL] [Abstract][Full Text] [Related]
4. Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.
Hickey JW; Vicente FP; Howard GP; Mao HQ; Schneck JP
Nano Lett; 2017 Nov; 17(11):7045-7054. PubMed ID: 28994285
[TBL] [Abstract][Full Text] [Related]
5. Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy.
Hou F; Guo Z; Ho MT; Hui Y; Zhao CX
ACS Nano; 2024 Mar; 18(12):8571-8599. PubMed ID: 38483840
[TBL] [Abstract][Full Text] [Related]
6. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
[TBL] [Abstract][Full Text] [Related]
7. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.
Sunshine JC; Perica K; Schneck JP; Green JJ
Biomaterials; 2014 Jan; 35(1):269-277. PubMed ID: 24099710
[TBL] [Abstract][Full Text] [Related]
8. DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy.
Sun L; Shen F; Xiong Z; Yang H; Dong Z; Xiang J; Gu Q; Ji Q; Fan C; Liu Z
J Am Chem Soc; 2022 May; 144(17):7634-7645. PubMed ID: 35438987
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372
[TBL] [Abstract][Full Text] [Related]
10. Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells.
Paine A; Oelke M; Blasczyk R; Eiz-Vesper B
Transfusion; 2007 Nov; 47(11):2143-52. PubMed ID: 17958544
[TBL] [Abstract][Full Text] [Related]
11. Cell-Templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigen-Presenting Cells for T Cell Activation.
Olden BR; Perez CR; Wilson AL; Cardle II; Lin YS; Kaehr B; Gustafson JA; Jensen MC; Pun SH
Adv Healthc Mater; 2019 Jan; 8(2):e1801188. PubMed ID: 30549244
[TBL] [Abstract][Full Text] [Related]
12. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
Small; 2017 Oct; 13(40):. PubMed ID: 28861943
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells.
Sayadmanesh A; Azadbakht M; Yari K; Abedelahi A; Shafaei H; Shanehbandi D; Baradaran B; Basiri M
Cell J; 2023 Oct; 25(10):674-687. PubMed ID: 37865876
[TBL] [Abstract][Full Text] [Related]
14. Artificial Antigen-Presenting Cell Fabrication for Murine T Cell Expansion.
Omotoso MO; Lanis MR; Schneck JP
Curr Protoc; 2024 Feb; 4(2):e976. PubMed ID: 38400601
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
16. Artificial Antigen-Presenting Cell Topology Dictates T Cell Activation.
Wauters AC; Scheerstra JF; Vermeijlen IG; Hammink R; Schluck M; Woythe L; Wu H; Albertazzi L; Figdor CG; Tel J; Abdelmohsen LKEA; van Hest JCM
ACS Nano; 2022 Sep; 16(9):15072-15085. PubMed ID: 35969506
[TBL] [Abstract][Full Text] [Related]
17. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.
Ye Q; Loisiou M; Levine BL; Suhoski MM; Riley JL; June CH; Coukos G; Powell DJ
J Transl Med; 2011 Aug; 9():131. PubMed ID: 21827675
[TBL] [Abstract][Full Text] [Related]
18. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
Choi H; Lee Y; Hur G; Lee SE; Cho HI; Sohn HJ; Cho BS; Kim HJ; Kim TG
Cytotherapy; 2021 Oct; 23(10):908-917. PubMed ID: 34312069
[TBL] [Abstract][Full Text] [Related]
19. Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.
Zhang L; Wang L; Shahzad KA; Xu T; Wan X; Pei W; Shen C
Cancer Immunol Immunother; 2017 Sep; 66(9):1229-1241. PubMed ID: 28501941
[TBL] [Abstract][Full Text] [Related]
20. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.
Eggermont LJ; Paulis LE; Tel J; Figdor CG
Trends Biotechnol; 2014 Sep; 32(9):456-65. PubMed ID: 24998519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
